Identification and Tracking of Antiviral Drug Combinations

Show simple item record

dc.contributor University of Helsinki, Institute for Molecular Medicine Finland en
dc.contributor University of Helsinki, Institute for Molecular Medicine Finland en Ianevski, Aleksandr Yao, Rouan Biza, Svetlana Zusinaite, Eva Mannik, Andres Kivi, Gaily Planken, Anu Kurg, Kristiina Tombak, Eva-Maria Ustav, Mart Shtaida, Nastassia Kulesskiy, Evgeny Jo, Eunji Yang, Jaewon Lysvand, Hilde Loseth, Kirsti Oksenych, Valentyn Aas, Per Arne Tenson, Tanel Vitkauskiene, Astra Windisch, Marc P. Fenstad, Mona Hoysaeter Nordbo, Svein Arne Ustav, Mart Bjoras, Magnar Kainov, Denis E. 2020-11-30T11:13:01Z 2020-11-30T11:13:01Z 2020-10
dc.identifier.citation Ianevski , A , Yao , R , Biza , S , Zusinaite , E , Mannik , A , Kivi , G , Planken , A , Kurg , K , Tombak , E-M , Ustav , M , Shtaida , N , Kulesskiy , E , Jo , E , Yang , J , Lysvand , H , Loseth , K , Oksenych , V , Aas , P A , Tenson , T , Vitkauskiene , A , Windisch , M P , Fenstad , M H , Nordbo , S A , Ustav , M , Bjoras , M & Kainov , D E 2020 , ' Identification and Tracking of Antiviral Drug Combinations ' , Viruses-Basel , vol. 12 , no. 10 , 1178 . en
dc.identifier.issn 1999-4915
dc.identifier.other PURE: 156522888
dc.identifier.other PURE UUID: 6a73c4ed-54f3-45d9-90a4-86dd6748b9bc
dc.identifier.other WOS: 000587455300001
dc.description.abstract Combination therapies have become a standard for the treatment for HIV and hepatitis C virus (HCV) infections. They are advantageous over monotherapies due to better efficacy, reduced toxicity, as well as the ability to prevent the development of resistant viral strains and to treat viral co-infections. Here, we identify new synergistic combinations against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), echovirus 1 (EV1), hepatitis C virus (HCV) and human immunodeficiency virus 1 (HIV-1) in vitro. We observed synergistic activity of nelfinavir with convalescent serum and with purified neutralizing antibody 23G7 against SARS-CoV-2 in human lung epithelial Calu-3 cells. We also demonstrated synergistic activity of nelfinavir with EIDD-2801 or remdesivir in Calu-3 cells. In addition, we showed synergistic activity of vemurafenib with emetine, homoharringtonine, anisomycin, or cycloheximide against EV1 infection in human lung epithelial A549 cells. We also found that combinations of sofosbuvir with brequinar or niclosamide are synergistic against HCV infection in hepatocyte-derived Huh-7.5 cells, and that combinations of monensin with lamivudine or tenofovir are synergistic against HIV-1 infection in human cervical TZM-bl cells. These results indicate that synergy is achieved when a virus-directed antiviral is combined with another virus- or host-directed agent. Finally, we present an online resource that summarizes novel and known antiviral drug combinations and their developmental status. en
dc.format.extent 15
dc.language.iso eng
dc.relation.ispartof Viruses-Basel
dc.rights en
dc.subject antivirals en
dc.subject antiviral drug combinations en
dc.subject broad-spectrum antivirals en
dc.subject virus en
dc.subject ENTRY en
dc.subject 11832 Microbiology and virology en
dc.title Identification and Tracking of Antiviral Drug Combinations en
dc.type Article
dc.description.version Peer reviewed
dc.type.uri info:eu-repo/semantics/other
dc.type.uri info:eu-repo/semantics/publishedVersion

Files in this item

Total number of downloads: Loading...

Files Size Format View
viruses_12_01178.pdf 3.380Mb PDF View/Open

This item appears in the following Collection(s)

Show simple item record